FEATURED STORIES

News

Ozempic makes list for next round of Medicare drug price negotiations

Endpoints News | Jan. 17, 2025

Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare negotiation program under the Inflation Reduction Act, following repeated calls from lawmakers to make the treatments more affordable.

The list came weeks before the government’s deadline, kicking off a new cycle that’s slated to take place under the incoming Trump administration. Together, the 15 drugs cost Medicare Part D about $41 billion from November 2023 through October 2024.

Combined with the first 10 drugs subject to Medicare negotiations, the 25 drugs accounted for 36% of Medicare Part D spending during the same period.

READ

ABOUT ME

Let's connect!

I am a senior reporter at Endpoints News, a leading news source for the biopharma industry and a publication of the Financial Times. I cover a variety of breaking news, features and health policy-related stories, particularly around the Inflation Reduction Act. I'm also a co-creator of the Endpoints Weekly, a newsletter that recaps the week's biggest news in biopharma.

Before Endpoints, I was a breaking news and general assignment reporter at the Lowell Sun. My coverage spanned court stories, local politics, early pandemic updates and more. I helped launch the Daily Sunrise, a curated morning newsletter that gained more than a thousand new subscribers in just a few months.

I'm a proud University of Massachusetts Amherst graduate with a degree in journalism and a minor in information technology. I've also written for the Boston Globe Magazine, Daily Hampshire Gazette, and Worcester Telegram & Gazette. When I'm not on deadline, you'll find me making homemade pasta or lost in a good book.

About